-
公开(公告)号：EP3503927A1
公开(公告)日：2019-07-03
申请号：EP17765518.0
申请日：2017-08-29
-
2.发明公开
公开(公告)号：EP3737415A1
公开(公告)日：2020-11-18
申请号：EP19738621.2
申请日：2019-01-08
-
公开(公告)号：EP2756061A1
公开(公告)日：2014-07-23
申请号：EP12876815.7
申请日：2012-05-16
CPC分类号： C07K1/145 , A61K8/466 , A61K8/86 , A61K2800/5422 , A61K2800/5428 , A61Q19/00 , A61Q19/02
摘要： Solubilizing compositions are provided. The compositions comprise at least one zwitterionic surfactant and at least one nonionic surfactant. In one embodiment, the compositions may be useful for solubilizing and remodeling and/or removing tissue on or beneath a patient's skin, optionally in conjunction with the application of energy to a region of interest on the skin. In one embodiment, at least one analyte may be collected and analyzed from the solubilized tissue.
-
4.发明公开IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY 审中-公开IONISCHEFLÜSSIGKEITENZUR TRANSDERMALEN ARZNEIMITTELVERABREICHUNG
公开(公告)号：EP3062819A2
公开(公告)日：2016-09-07
申请号：EP14859243.9
申请日：2014-11-03
发明人： ZAKREWSKY, Michael , MITRAGOTRI, Samir , FOX, David T. , KOPPISCH, Andrew , DEL SESTO, Rico , LOVEJOY, Katherine
CPC分类号： A61K47/24 , A01N33/12 , A01N43/36 , A61K9/0014 , A61K31/047 , A61K31/545 , A61K31/66 , A61K47/12 , A61K47/186 , A01N41/06 , A01N37/02 , A01N37/04 , A01N37/06 , A01N47/28 , A01N49/00
摘要： IIONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY ABSTRACT The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.
摘要翻译： 本文描述的组合物和方法局部施用于具有可忽略或无皮肤刺激性的皮肤，并且可以引导或预防通过皮肤的运输。 组合物含有纯的离子液体，任选地与待递送的药物组合。 在优选的实施方案中，组合物增加待递送药物的透皮转运。 在一些实施方案中，组合物破坏细菌生物膜。 这对抗生素抗性皮肤感染的治疗特别有益。 在其它实施方案中，组合物在皮肤内直接递送。 在其它实施方案中，组合物防止物质通过角质层转移。 所公开的组合物和方法可以被调整和修饰，使得它们可以用于治疗或预防多种不同的疾病和病症。
-
公开(公告)号：EP2396654A2
公开(公告)日：2011-12-21
申请号：EP10741763.6
申请日：2010-02-12
发明人： MITRAGOTRI, Samir , OGURA, Makoto , PALIWAL, Sumit
IPC分类号： G01N33/487 , G01N33/48 , A61B10/02 , A61M27/00
CPC分类号： A61B10/02 , A61B10/0045 , A61B10/0096 , A61B10/0283 , A61B10/04 , A61B18/04 , A61B18/20 , A61B2010/0208 , A61B2017/00761 , A61B2017/320004 , A61B2018/00452 , A61K31/522 , A61K38/28 , A61M37/0015 , A61M2037/0023 , A61M2037/0046 , A61N7/00 , A61N7/02 , A61N2007/0034 , C12M23/28 , C12M31/00 , C12M35/08 , G01N1/286 , G01N1/4044 , G01N1/44 , Y10T436/2575
摘要： The current invention provides devices, methods and systems involving application of energy and/or a liquefaction promoting medium to a tissue of interest to generate a liquefied sample comprising tissue constituents so as to provide for rapid tissue sampling, tissue decontamination as well as qualitative and/or quantitative detection of analytes that may be part of tissue constituents (e.g., several types ofbiomolecules, drugs and microbes). In addition, the current invention provides specific compositions of the said liquefaction promoting medium so as to facilitate liquefaction, preserve liquefied tissue constituents, and enable delivery of molecules into tissues. Determination of tissue composition in the liquefied tissue sample can be used in a variety of applications, including diagnosis or prognosis of local as well as systemic diseases, evaluating bioavailability of therapeutics in different tissues following drug administration, forensic detection of drugs-of-abuse, evaluating changes in the tissue microenvironment following exposure to a harmful agent, and various other applications. The methods, devices and systems are used to deliver one or more drugs through or into the site of the tissue to be liquefied.
-
公开(公告)号：EP3709974A1
公开(公告)日：2020-09-23
申请号：EP18878738.6
申请日：2018-11-16
-
7.发明公开
公开(公告)号：EP3307338A1
公开(公告)日：2018-04-18
申请号：EP16808484.6
申请日：2016-06-11
IPC分类号： A61L27/52 , A61L27/20 , A61L27/14 , A61L27/54 , A61L27/22 , A61L27/38 , A61K9/00 , A61K31/728
CPC分类号： C08B37/0072 , A61K9/0014 , A61K9/06 , A61K31/728 , A61K45/06 , A61K47/36 , A61L27/20 , A61L27/38 , A61L27/52 , A61L27/54 , A61L2300/402 , A61L2300/406 , A61L2300/414 , A61L2300/436 , A61L2400/06 , A61M5/19 , A61M5/31596 , C07K16/283 , C08L5/08
摘要： Provided herein are novel hyaluronic acid-based materials for in-situ gelation in wounds and other contexts, which materials are biocompatible and which have favorable gelation kinetics. The resulting hydrogels have desirable rheological properties. The invention encompasses novel reagents for forming crosslinked hyaluronic acid hydrogels, with favorable kinetics for medical applications and having desirable and tunable physical properties. Also presented herein are methods of using the novel materials disclosed herein in wound care and other medical contexts.
-
公开(公告)号：EP3267975A1
公开(公告)日：2018-01-17
申请号：EP16762441.0
申请日：2016-03-09
CPC分类号： A61K47/61 , A61K31/4745 , A61K31/704 , A61K31/7068
摘要： Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.
-
公开(公告)号：EP3380082A2
公开(公告)日：2018-10-03
申请号：EP16816494.5
申请日：2016-11-23
IPC分类号： A61K9/127 , A61K31/505 , A61K31/70 , A61P35/00 , A61K31/704
CPC分类号： A61K31/505 , A61K9/127 , A61K9/1278 , A61K31/70 , A61K31/704 , A61K2300/00
摘要： Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.
-
公开(公告)号：EP2968889A1
公开(公告)日：2016-01-20
申请号：EP14762727.7
申请日：2014-03-17
CPC分类号： A61M37/0092 , A61B18/203 , A61B2018/0047 , A61B2018/00476 , A61B2018/00577 , A61K9/0009 , A61K9/0014 , A61K9/10 , A61K9/127 , A61K9/501 , A61K9/5031 , A61K9/5073 , A61K9/5078 , A61K9/51 , A61K9/5115 , A61K9/5146 , A61K41/0047 , A61M2037/0007 , A61M2210/04 , A61N5/062 , A61N2005/067 , B82Y5/00
摘要： Improved methods for treating a sebaceous gland disorder, such as acne, are described. The methods include a) cleaning the skin site with a solvent by applying immersion low frequency ultrasound to the site; b) delivering nanoshell particles into the infundibula and sebaceous glands over a period of time, by applying iontophoresis, low frequency ultrasound, or electroporation, or a combination thereof, preferably administering immersion low frequency ultrasound; and c) thermally activating the nanoshell particles to modify or destroy the infundibula and sebaceous gland are provided. A sufficient amount of the nanoshell particles infiltrates spaces about the sebaceous glands and is exposed to energy to cause the particles to become thermally activated. Photothermal activation of the nanoshell particles brings about a physiological change in the sebaceous gland, thereby treating the sebaceous gland disorder. Preferably, the sebaceous gland is destroyed. There is minimal to no destruction of normal adjacent epidermal and dermal structures.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.018 秒)
